Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

Last updated: November 18, 2021
Sponsor: Sun Pharmaceutical Industries Limited
Overall Status: Completed

Phase

3

Condition

Inflammation

Uveitis

Eye Disease

Treatment

N/A

Clinical Study ID

NCT01808547
C-12-303-004
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the ocular safety, tolerability and efficacy of topical administration of ISV-303 compared with Durasite Vehicle.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female subjects age 18 or older scheduled for unilateral cataract surgery withposterior chamber intraocular lens implantation
  • If a female is of childbearing potential, the subject must agree to and submit anegative pregnancy test before any protocol-specific procedures are conducted. Thesubject must use effective contraception for the duration of the study. Postmenopausal is defined as having no menses for at least 12 consecutive months
  • Signature of the subject on the Informed Consent Form
  • Willing to avoid disallowed medications for the duration of the study
  • Willing and able to follow all instructions and attend all study visits
  • Able to self-administer the IMP (or have a caregiver available to instill all doses ofstudy drugs )
  • Additional inclusion criteria also apply

Exclusion

Exclusion Criteria:

  • Known hypersensitivity or poor tolerance to bromfenac sodium or any component of theIMP or any of the procedural medications
  • Currently pregnant, nursing, or planning a pregnancy; or be a woman that has apositive pregnancy test
  • Currently suffer from alcohol and/or drug abuse
  • Prior (within 30 days of beginning study treatment) or anticipated concurrent use ofan investigational drug or device
  • A condition or a situation, which in the investigator's opinion may put the subject atincreased risk, confound study data, or interfere significantly with the subject'sstudy participation
  • Additional inclusion criteria also apply

Study Design

Total Participants: 268
Study Start date:
May 01, 2013
Estimated Completion Date:
November 30, 2013

Connect with a study center

  • Arizona Eye Center

    Chandler, Arizona 85225
    United States

    Site Not Available

  • Cornea Consultants of Arizona

    Phoenix, Arizona 85032
    United States

    Site Not Available

  • Eye Research Foundation

    Newport Beach, California 92663
    United States

    Site Not Available

  • Martel Eye Medical Group

    Rancho Cordova, California 95670
    United States

    Site Not Available

  • West Coast Eye Care Associates

    San Diego, California 92115
    United States

    Site Not Available

  • Andrew Gardner Logan dba Logan Ophthalmic Research, LLC

    Tamarac, Florida 33321
    United States

    Site Not Available

  • Great Lakes Eye Care

    St.Joseph, Michigan 49085
    United States

    Site Not Available

  • Tauber Eye Center

    Kansas City, Missouri 64111
    United States

    Site Not Available

  • Tekwani Vision Center

    St. Louis, Missouri 63148
    United States

    Site Not Available

  • Ophthalmology Associates

    St.Louis, Missouri 63131
    United States

    Site Not Available

  • Cornerstone Health Care

    High Point, North Carolina 27262
    United States

    Site Not Available

  • James D. Branch, MD

    Winston-Salem, North Carolina 27101
    United States

    Site Not Available

  • Total Eye Care,P.A

    Memphis, Tennessee 38119
    United States

    Site Not Available

  • David G. Shulman, MD

    San Antonio, Texas 78209
    United States

    Site Not Available

  • DCT Kumar, LLc dba Discovery Clinical Trials

    Uvalde, Texas 78801
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.